# 2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients.

*biotech · news · 2026-04-13 · The Manila Times*

## Key points

- Biologic therapies are now used in nearly 60% of moderate-to-severe SLE patients.
- Subcutaneous Saphnelo is expected to drive significant patient switching from Benlysta due to convenience.
- Only 11% of SLE patients are in remission, with nearly half still experiencing moderate or high disease activity.
- One in five rheumatologists have referred a patient to a cell therapy trial for SLE in the past year.
- A substantial portion of SLE patients remain biologic-eligible but untreated, representing growth potential for new therapies.

**Companies:** AstraZeneca, GSK, Biogen, Genentech, Bristol Myers Squibb, AbbVie
**Countries:** United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/13/tmt-newswire/globenewswire/sle-market-evolution-accelerates-as-astrazenecas-saphnelo-sc-emerges-as-a-likely-key-challenger-to-gsks-benlysta/2319272)

---

Canonical: https://newsio.io/n/a6818065-aaec-4d8d-8918-8af3a137795a/2026-patient-audit-data-from-spherix-global-insights-reveals-biologic-use-nearin
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works